StockDrifts LogoStockDrifts

Kookjeon Pharmaceutical 307750

Company
국전약품Kookjeon Pharmaceutical
Insiders
1
Buys
1
Total Value
₩11M ($8K)
Avg Return
-43.53%
Last Filing
2024-05-07

Kookjeon Pharmaceutical (307750) has 1 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩11M ($8K) in reported transaction value. The earliest filing StockDrifts holds for Kookjeon Pharmaceutical is dated 2024-04-01; the most recent is 2024-05-07. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -43.53%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-07-21SELL증여
홍종훈
Hong Jong-hoon
Managing Director (Assistant)-50.0K₩2,005-3.7%₩100M ($70K)
2026-07-21SELL증여
홍종훈
Hong Jong-hoon
Managing Director (Assistant)-50.0K₩2,005-3.7%₩100M ($70K)
2026-07-16BUY상속
홍종훈
Hong Jong-hoon
Managing Director (Assistant)139.6K₩2,060+1.0%₩288M ($200K)
2024-05-07BUYMarket Buy
최성열
Seongyeol Choi
Managing Director (Assistant)2.0K₩5,640-43.5%₩11M ($8K)
2024-04-01BUY신규선임
최성열
Seongyeol Choi
Managing Director (Assistant)1.0K₩6,250-49.0%₩6M ($4K)

Frequently asked questions

Who has been buying Kookjeon Pharmaceutical stock?
1 distinct insiders have filed 1 disclosed insider purchases in Kookjeon Pharmaceutical (307750), most recently on 2024-05-07. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Kookjeon Pharmaceutical have?
Kookjeon Pharmaceutical has 1 buy-side and 0 sell-side disclosures on record, covering ₩11M ($8K) in total reported value, spanning 2024-04-01 to 2024-05-07.
Where does StockDrifts get Kookjeon Pharmaceutical insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Kookjeon Pharmaceutical. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.